Literature DB >> 8425584

Lung adenocarcinoma with type II pneumocyte characteristics.

S Tsutahara1, N Shijubo, M Hirasawa, Y Honda, M Satoh, Y Kuroki, T Akino.   

Abstract

We report a case of primary lung adenocarcinoma with type II pneumocyte characteristics. Electron microscopic examination demonstrated that the tumour cells had well-developed microvilli and cytoplasmic lamellar inclusion bodies. These ultrastructural features are similar to those seen in type II pneumocytes of normal lung tissue. Western blot analysis, using monoclonal antibody against human surfactant protein A (SP-A), clearly demonstrated that the tumour cells expressed human SP-A, which is a major pulmonary surfactant protein produced by type II pneumocytes. These observations suggest that the tumour was derived from a type II pneumocyte.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425584

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

Review 1.  Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.

Authors:  Min-Ae Song; Neal L Benowitz; Micah Berman; Theodore M Brasky; K Michael Cummings; Dorothy K Hatsukami; Catalin Marian; Richard O'Connor; Vaughan W Rees; Casper Woroszylo; Peter G Shields
Journal:  J Natl Cancer Inst       Date:  2017-12-01       Impact factor: 13.506

2.  Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.

Authors:  A S Abutaily; B J Addis; W R Roche
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

3.  The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer.

Authors:  Yu Wang; Weihan Yang; Qiang Pu; Yan Yang; Sujuan Ye; Qingping Ma; Jiang Ren; Zhixing Cao; Guoxing Zhong; Xuechao Zhang; Lunxu Liu; Wen Zhu
Journal:  J Biomed Sci       Date:  2015-07-09       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.